UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 68,253 Shares of Corvus Pharmaceuticals, Inc. $CRVS

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 1,116.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 74,369 shares of the company’s stock after buying an additional 68,253 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Corvus Pharmaceuticals were worth $1,111,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of CRVS. Global Retirement Partners LLC acquired a new position in Corvus Pharmaceuticals in the second quarter valued at about $30,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Corvus Pharmaceuticals during the second quarter worth about $48,000. Quarry LP acquired a new stake in Corvus Pharmaceuticals during the third quarter worth about $27,000. State of Wyoming bought a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $71,000. Finally, Meeder Asset Management Inc. bought a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $90,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

Corvus Pharmaceuticals stock opened at $12.91 on Friday. Corvus Pharmaceuticals, Inc. has a 52 week low of $5.64 and a 52 week high of $26.95. The stock has a market capitalization of $1.09 billion, a P/E ratio of -21.16 and a beta of 0.87. The stock has a fifty day moving average of $14.31 and a 200-day moving average of $14.37.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). On average, research analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.79 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on CRVS shares. LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, July 30th. Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.33.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the immune system to treat cancer and other serious diseases. The company’s research is centered on small-molecule and antibody-based therapies designed to influence immune-cell activity and improve the body’s ability to respond to disease.

Corvus’ lead investigational product is soquelitinib, also known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK).